5-HT7 Receptor Modulators via Fluorinated Lactone Derivatives

The patent modifies the chemical structure of 5-HT7 receptor modulators by changing parameters such as substituting hydrogen atoms at specific positions (e.g., positions 2 and/or 6 of the phenyl ring) with fluorine atoms, introducing specific functional groups, and adjusting molecular weight and lipophilicity. These parameter changes result in compounds with improved binding affinity, selectivity, and therapeutic efficacy across multiple disorders including depression, anxiety, and circadian rhythm disorders.

The patent creates composite molecular structures by combining different pharmacophores and functional groups within a single molecule. Examples include compounds that integrate indole core structures with various substituent patterns (e.g., fluorinated phenyl groups, pyridine rings, and carboxylic acid moieties), creating multi-functional molecules that can modulate 5-HT7 receptor activity while providing additional therapeutic benefits.

The patent divides the molecular structure into distinct functional segments: a core indole pharmacophore responsible for 5-HT7 receptor binding, substituent groups at specific positions (e.g., fluorinated phenyl groups at positions 2 and/or 6), and additional functional moieties (e.g., carboxylic acid, amide groups) that provide therapeutic specificity. This segmentation allows independent optimization of each component's contribution to binding affinity and therapeutic effect.

The patent introduces specific functional groups and substituents at localized positions within the molecular structure to achieve precise modulation of receptor activity. For example, fluorine atoms are strategically placed at positions 2 and/or 6 of the phenyl ring to enhance binding affinity, while carboxylic acid groups are positioned to interact with specific receptor residues. This local modification approach improves therapeutic efficacy without requiring complete redesign of the entire molecule.